Drug Profile
Research programme: cardiovascular disease therapy - Kereos
Alternative Names: Cardiovascular disease therapy research programme - Kereos; KI-1003Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kereos
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 03 Oct 2006 A preclinical study has been added to the Vascular disorders pharmacodynamics section